Compare FuelCell Energy Inc (FCEL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Recursion Pharmaceuticals Inc — how do they compare? FuelCell Energy Inc trades at $17.84 (market cap $1.62B), while Recursion Pharmaceuticals Inc trades at $3.16 (market cap $1.75B). The key difference: FuelCell Energy Inc and Recursion Pharmaceuticals Inc are close in size by market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| FCEL | RXRX | |
|---|---|---|
Market Cap | $1.62B | $1.75B |
Sector | Industrials | Health |
52-Week High | $36.01 | $6.79 |
52-Week Low | $3.92 | $2.84 |
Enterprise Value | $1.47B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $21.35, up 11.9% in the last 24 hours, reflecting high volatility amid recent news. The stock shows a neutral technical signal with bearish moving averages, while fundamentals reveal persistent losses with a net income margin of -132.41% in 2025 despite revenue growth to $158.16M. Recent developments include a strategic partnership with Siemens to scale clean power solutions and a $225M stock offering that caused temporary dilution concerns.
The outlook is mixed: analyst consensus is balanced with a $20.75 price target, but continued cash burn and high valuation multiples pose risks. Opportunities lie in AI-driven data center demand, though profitability remains a key challenge for sustainable upside.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
